Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 7/20 | 0.43 |
| ▸ | MTTP | P55157 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11086633 | 0.80 | SCN1A (0.40) | — | |
| SCHEMBL5863723 | 0.78 | THRB (0.46) | PDK2MTTPAPEX1 | |
| SCHEMBL7610982 | 0.78 | PDK2 (0.40) | PDK2APEX1 | |
| SCHEMBL6777657 | 0.77 | APEX1 (0.40) | MTTPAPEX1 | |
| SCHEMBL5863866 | 0.77 | APEX1 (0.40) | PDK2MTTPAPEX1 | |
| Hydrochloric Acid SCHEMBL6777668 | 0.77 | THRB (0.44) | PDK2MTTPAPEX1 | |
| SCHEMBL5863337 | 0.77 | GLA (0.40) | PDK2MTTP | |
| SCHEMBL5863393 | 0.77 | MTTP (0.47) | PDK2MTTP | |
| SCHEMBL7045213 | 0.76 | MTTP (0.39) | PDK2MTTPAPEX1 | |
| Propionamide SCHEMBL27574379 | 0.76 | THRB (0.38) | MTTPAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | MTTP, CETP, LIPC | PDK2 2312/4885MTTP 1/4885SLC6A2 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.